Enrico Michler and David Kästner contributed equally to this work.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
212Pb is a promising radionuclide for targeted alpha particle therapy for cancer. Ongoing preclinical and clinical studies are investigating the potential of 212Pb-labeled peptides and antibodies [1‐5]. PSC-PEG2-TOC (VMT-α-NET) is a novel somatostatin receptor subtype 2 (SSTR2) targeting peptide for the treatment of neuroendocrine tumors (NET) that shows rapid tumor accumulation, high tumor retention, and fast renal excretion with the potential for low nephrotoxicity [6, 7].
Here, we present the case of a 75-year-old woman with an advanced G2 NET of unknown primary with liver metastases who was heavily pretreated with somatostatin analogs, various chemotherapies, multiple cycles of [177Lu]Lu-DOTA-TATE and [225Ac]Ac-DOTA-TATE, and radioembolization over 7 years. The patient received 90 MBq of [212Pb]Pb-VMT-α-NET intravenously. Whole-body scintigraphy and SPECT/CT acquisitions were performed 2, 5, and 19 h after injection on a Symbia Intevo 6 (Siemens Healthineers) using high-energy collimators. Images were obtained by detection of the characteristic X-ray emissions of 212Pb using an energy window at 79 keV (40% width). The whole-body scan speed was 8 cm/min, and SPECT/CT scans were acquired with 120 projections (60 per detector, 30 s per projection) over a non-circular 360° orbit. The SPECT/CT images showed a high accumulation of [212Pb]Pb-VMT-α-NET in liver metastases in segments III and IV, consistent with the previously acquired [68Ga]Ga-DOTA-TATE PET/CT. High tumor retention can be observed in the planar and SPECT/CT images over time. The planar images showed a high level of background noise due to down-scatter and septal penetration of high-energy photon emissions from 212Pb daughter nuclides (e.g., 2.6 MeV from 208Tl). Due to the short half-life of 212Pb (10.6 h), the images acquired after 19 h showed a relatively high level of image noise due to the low count statistics. The patient showed no early or acute adverse events.
Anzeige
These are the first clinical post-treatment scintigraphic images of [212Pb]Pb-VMT-α-NET and additionally the first-in-human SPECT/CT images of 212Pb.
×
Acknowledgements
The 212Pb isotope generator for the production of the radiopharmaceutical used in this study was provided by Perspective Therapeutics, Inc.
Declarations
Ethics approval and consent to participate
Written informed consent was obtained from the patient for the treatment procedure and for data publication.
Conflict of interest
The author Michael K. Schultz is the CSO (Chief Science Officer) of Perspective Therapeutics, Inc. The other authors declare no other competing interests.
Anzeige
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Mit e.Med Radiologie erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Radiologie, den Premium-Inhalten der radiologischen Fachzeitschriften, inklusive einer gedruckten Radiologie-Zeitschrift Ihrer Wahl.
